Cite

    Gary Brown et al.. “The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited.” International journal of retina and vitreous, vol. 3, no. 1, 2017, pp. 1–11. http://access.bl.uk/ark:/81055/vdc_100081111956.0x000006